首页> 外文期刊>Nature >New biological targets for lowering LDL levels
【24h】

New biological targets for lowering LDL levels

机译:降低LDL水平的新生物学靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Here we consider biological targets that may reduce LDL levels to a greater extent than that obtained by high-dose statin therapy. Niemann-Pick C1-like protein 1 Inhibition of the intestinal cholesterol transporter Niemann-Pick Cl-like protein 1 (NPC1 L1) by the agent ezetimibe can reduce LDL levels by almost 20% in individuals already being treated with statins. Although combined therapy with statins and ezetimibe can help more individuals to reach mandated LDL targets for their level of risk, no clinical trial data have so far shown that this strategy will lower cardiovascular event rates beyond the drop produced by statin monotherapy. Studies of biomarkers such as the thickness of the carotid artery intima media, flow-mediated vasodilation, or inflammation cannot supplant lacking of data on clinical events. This example emphasizes three important points: (1) the need to choose biomarkers carefully to be pursued in clinical development; (2) the ultimate requirement for clinical end-point studies to determine the efficacy of interventions; and (3) the value of starting such definitive studies early in drug-development programmes.
机译:在这里,我们考虑的生物靶标可能比通过大剂量他汀类药物治疗所获得的靶标降低程度更大。 Niemann-Pick C1样蛋白1依泽替米贝对肠胆固醇转运蛋白Niemann-Pick C1样蛋白1(NPC1 L1)的抑制作用可以使已经接受他汀类药物治疗的患者的LDL水平降低近20%。尽管将他汀类药物和依泽替米贝联合治疗可以帮助更多的个人达到其风险水平所需的低密度脂蛋白目标,但迄今为止,尚无临床试验数据表明该策略可将心血管事件的发生率降低到他汀类药物单一疗法所致的下降水平以下。诸如颈动脉内膜中层厚度,血流介导的血管舒张或炎症等生物标志物的研究不能取代缺乏临床事件数据的现象。这个例子强调了三个要点:(1)在临床开发中必须谨慎选择生物标志物; (2)确定干预效果的临床终点研究的最终要求; (3)在药物开发计划中尽早开展此类确定性研究的价值。

著录项

  • 来源
    《Nature》 |2011年第7347期|p.319|共1页
  • 作者

  • 作者单位
  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号